During Tuesday’s current trade, Nokia Corporation (NYSE:NOK)’s shares dropped -3.98% to $7.97, trading with huge volume of 40,909,259 shares now, after Nokia revealed Tuesday it’s in advanced talks to buy the ailing French telecoms company Alcatel-Lucent, an apparent bid to become a leading global networks operator.
Hopes for a deal were boosted by news that the French government, which has a history of intervening in takeover attempts by foreign companies, would give its blessing.
In a brief statement, Nokia Corp. said the two companies are in negotiations “with respect to a potential full combination which would take the form of a public exchange offer by Nokia for Alcatel-Lucent.”
The Finnish company gave no details of the talks and denied further comment except to say that a further declaration would be made when appropriate.
Both companies’ chief executives, Nokia’s Rajeev Suri and Alcatel-Lucent’s Michel Combes, met with French President Hollande briefly on Tuesday afternoon but did not talk to reporters after the meeting. The French government said it would support the deal.
On the other hand, Alcatel-Lucent (NYSE:ALU), boosted 8.97% on this news to $4.74, hitting its highest level today. The stock is trading with high volume, and is the second most active stock for now.
Nokia Corporation, together with its auxiliaries, provides network infrastructure and related services in Finland, the United States, Japan, China, India, the Russian Federation, Germany, Taiwan, Indonesia, Italy, and internationally. The company operates through four segments: Mobile Broadband, Global Services, HERE, and Nokia Technologies.
Alcatel-Lucent provides Internet protocol (IP) and cloud networking, and ultra- broadband access worldwide. The company’s Core Networking segment offers IP routing, carrier Ethernet, network functions virtualization, and software defined networking applications and infrastructure to meet the challenges of network traffic growth while supporting the delivery of cloud-enabled business, mobile, and residential services for service providers, mobile network operators, cable/multiple system operators, transportation, utilities, and large-scale enterprises.
However, in relation to the above stated news, Ciena Corporation (NYSE:CIEN)’s stock also surged 6.93% to $21.30.
News of the potential deal assisted bring up shares of other communication equipment makers counting Ciena and Infinera (NASDAQ:INFN). Ciena and Alcatel-Lucent compete in the optical transport and switching market.
About 3.8 million shares of Ciena were traded by 10:07 a.m. Tuesday, above the company’s average trading volume of about 2.8 million shares a day.
Ciena Corporation provides equipment, software, and services that support the transport, switching, aggregation, service delivery, and management of voice, video, and data traffic on communications networks worldwide.
Infinera Corporation provides optical transport networking equipment, software, and services for telecommunications service providers, Internet content providers, cable operators, wholesale and enterprise carriers, research and education institutions, and government entities worldwide.
Finally, BioLife Solutions, Inc. (NASDAQ:BLFS)’s shares climbed 26.70% to $2.42, after BioLife Solutions declared preliminary proceed of $1.5 million for the first quarter of 2015 comprised entirely of core proprietary product proceed, representing 30% growth over the same period of 2014.
Proprietary proceed growth was driven by a 92% year over year raise from customers in the regenerative medicine segment. Several new regenerative medicine customers commenced product evaluations in the quarter and others started using CryoStor and HypoThermosol to preserve cell-based therapeutics in clinical trials focused on various cancers counting leukemia, melanoma, renal cancer, liver cancer, in addition to limb ischemia and dermal defects.
Administration estimates that the Company’s proprietary biopreservation media products are being used to preserve living human cells in at least 185 pre-clinical projects and clinical trials in the regenerative medicine market segment. Within the cellular immunotherapy segment of the regenerative medicine market, BioLife’s products are embedded in the manufacturing, storage, and delivery processes of at least 75 clinical trials of chimeric antigen receptor T cells (CAR-T), T cell receptor (TCR), dendritic cell (DC), tumor infiltrating lymphocytes (TIL), and other T cell-based cellular therapeutics targeting solid tumors, hematologic malignancies, and other diseases and disorders.
Other developments during the quarter comprised of:
- Continued progress on the development and pre-launch activities of the biologistex service for cold chain administration of biologic payloads.
- Expansion of intellectual property protection with the granting of new Australian patent number 2009228056 titled, “Materials and Methods for Hypothermic Collection of Whole Blood”.
- Dr. Aby J. Mathew, PhD, Chief Technology Officer, was designated to the founding board of directors of the newly formed Cord Blood Association.
- Kevin O’Donnell, Vice President, Cold Chain Standards, Practices, and Compliance was named 2014 Distinguished Editor/Author of the Year by the Parenteral Drug Association, for his published book “Cold Chain Chronicles”.
BioLife Solutions, Inc. develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions for cells and tissues in the United States. The company’s products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, delayed-onset cell damage, and death.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
